This low-cost mission is still only getting started, and it's taking bigger risks than typical big-ticket NASA missions.

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $32.70 / share. This is an increase of 60.82% from the prior estimate of $20.34 dated December 3, 2025. The ...

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

Kodiak Sciences (KOD) has priced an expanded public offering of approximately 6.96 million shares at $23.00 each. The company expects to raise roughly $160 million in gross proceeds. Kodiak Sciences ...